5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1533-1537

  Choi, Eun Jeong ^a   Kim, Gun Hee ^a  

^a Duksung Women's University   (South Korea)

Author keywords

Akt pathway; Apigenin; Apoptosis; ErbB2; MDA MB 453 cells

Indexed keywords

APIGENIN; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APIGENIN; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2;

EID: 70449419900     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000598     Document Type: Article

References (28)

1. Bunnell CA and Winer EP: Oral 5-FU analogues in the treatment of breast cancer. Oncology 12: 39-43, 1998.
2. Cameron DA, Gabra H and Leonard RC: Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70: 120-124, 1994.
3. Miean KH and Mohamed S: Flavonoid (myricetin, quercetin, kaempferol, luteolin and apigenin) content of edible tropical plants. J Agric Food Chem 49: 3106-3112, 2001.
4. Soares R and Azevedo I: Apigenin: is it a pro- or anti-inflammatory agent? Am J Pathol 168: 1762-1763, 2006.
5. Fuchs J and Milbradt R: Skin anti-inflammatory activity of apigenin-7-glucoside in rats. Arzneimittelforschung 43: 370-372, 1993.
6. Singh JP, Selvendiran K, Banu SM, Padmavathi R and Sakthisekaran D: Protective role of Apigenin on the status of lipid peroxidation and antioxidant defense against hepato-carcinogenesis in Wistar albino rats. Phytomedicine 11: 309-314, 2004.
7. Romanová D, Vachálková A, Cipák L, Ovesná Z and Rauko P: Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. Neoplasma 48: 104-107, 2001.
8. Way TD, Kao MC and Lin JK: Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 279: 4479-4489, 2004.
9. Lindenmeyer F, Li H, Menashi S, Soria C and Lu H: Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr Cancer 39: 139-147, 2001.
10. Gupta S, Afag F and Mukhtar H: Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287: 914-920, 2001.
11. Chiang LC, Ng LT, Lin IC, Kuo PL and Lin CC: Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett 237: 207-214, 2006.
12. Czeczot H, Tudek B, Kusztelak J, Szymczyk T, Dobrowolska B, Glinkowska G, Malinowski J and Strzelecka H: Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res 240: 209-216, 1990.
13. Yin F, Giuliano AE, Law RE and van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21: 413-420, 2001.
14. Choi EJ and Kim GH: Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J Nutr Biochem 20: 693-690, 2008.
15. Chen X, Yeung TK and Wang Z: Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 277: 757-763, 2000.
16. Tan M, Yao J and Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205, 1997.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
18. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
19. Patel D, Shukla S and Gupta S: Apigenin and cancer chemoprevention: progress, potential and promise (Review). Int J Oncol 30: 233-245, 2007.
20. Lin JK, Chen YC, Huang YT and Lin-Shiau SY: Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem (Suppl) 28-29: 39-48, 1997.
21. Way TD, Kao MC and Lin JK: Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/ neu-overexpressing breast cancer cells. FEBS Lett 579: 145-152, 2005.
22. Kanathur N, Shantaveerapa HN, Byrd RP Jr, Mehta JB and Roy TM: Non-tubercular mycobacterial pulmonary infection in immunocompetent men. South Med J 94: 719-723, 2001.
23. West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248, 2002.
24. Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/ PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198, 2008.
25. Ruiz PA and Haller D: Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr 136: 664-671, 2006.
26. Kim WK, Bang MH, Kim ES, Kang NE, Jung KC, Cho HJ and Park JH: Quercetin decreases the expression of ErbB2 and ErbB3 proteins in HT-29 human colon cancer cells. J Nutr Biochem 16: 155-162, 2005.
27. Lee WJ, Chen WK, Wang CJ, Lin WL and Tseng TH: Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226: 178-191, 2008.
28. Long X, Fan M and Bigsby RM: Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Mol Cancer Ther 7: 2096-2108, 2008.